The average decrease of anticancer drugs is 56.7%! All regions began to implement and link up one after another

[China Pharmaceutical network industry trends] accelerate the implementation of anti-cancer drug price and supply guarantee and other related measures! Recently, the State Medical Security Bureau issued the notice on including 17 kinds of anticancer drugs into the category B scope of the national basic medical insurance, work injury insurance and maternity insurance drugs catalogue, and simultaneously determined the medical insurance payment standards for these drugs It is understood that the average decrease of the payment standard of 17 new anti-cancer drugs included in the medical insurance compared with the retail price is 56.7% Patients are expected to buy the reduced anti-cancer drugs before the end of November Compared with that before the negotiation, the average price of these 17 anticancer drugs decreased by 56.7%, and the payment standard of most imported drugs after the negotiation was lower than the market price of surrounding countries or regions, with an average of 36% After the introduction of the policy, all regions have started to take action to implement and link up the policy It is reported that the Fujian Medical Insurance Office recently announced that the 17 anti-cancer drugs will be included in the category B scope of the Fujian medical insurance drug catalog, and will be implemented in accordance with the limited payment scope stipulated by the state from 25th of this month According to the principle of classified management, combined with the payment ability of local medical insurance fund, the provincial medical insurance office requires each overall planning area of Fujian Province to reasonably determine the proportion of individual self payment in advance for drugs negotiated by the state The proportion of individuals who pay for 17 kinds of anticancer drugs at the provincial level is 30% Zhejiang Province has also launched 17 kinds of national anti-cancer drugs into the province's medical insurance payment since November 1 It is reported that in order to let the insured people in Zhejiang enjoy the benefits of the national anti-cancer drug negotiation as soon as possible, the Provincial Department of human resources and social security organized relevant departments to study the landing and connection policies, formulated and issued the letter on Forwarding (zhrsh [2018]), and defined the time table and road map implemented in Zhejiang Province According to the industry, the average decrease of payment standard of negotiated drugs is 56.7%, which will greatly reduce the drug burden of cancer patients in China However, some insiders said that entering the medical insurance is only a step How to ensure that 17 kinds of anti-cancer drugs can enter the hospital is more important According to the state health insurance bureau, patients will be able to buy cancer drugs at reduced prices by the end of November In this process, we will coordinate and cooperate with relevant departments to strengthen the guidance for doctors in drug use, ensure the purchase and rational use of anti-cancer drugs, and ensure that drugs can be purchased by patients in hospitals In addition, some people in the industry said that it's a good thing to reduce the price of anticancer drugs by a large margin, but it's not until the "success" time, "we also need to ensure that we can buy and continue to supply, which is a follow-up article that needs to be highly valued and well done." In order to ensure production and supply, relevant departments should implement various preferential policies such as tax reduction, exemption and subsidy for domestic pharmaceutical enterprises, fully mobilize the enthusiasm of enterprises in the production of anti-cancer drugs for price reduction, strengthen communication and coordination with foreign enterprises, urge foreign suppliers to strictly implement the negotiation agreement, ensure the continuous supply of anti-cancer drugs for price reduction, and at the same time, try to adopt direct marketing to reduce the procurement link and reduce the cost Low drug cost Cancer has become an important cause of death for Chinese residents According to the data, the market scale of anti-tumor drugs in China has exceeded 120 billion yuan in 2017 It is the focus of our country's attention to solve the problem of high price anticancer drugs and make cancer patients use good drugs The inclusion of anticancer drugs in the medical insurance is a great blessing for cancer patients In addition, in the short and medium term, the tumor innovative drugs will start a new cycle of large-scale after the medical insurance negotiation "In the long run, we believe that in the future, medical insurance will be more and more involved in the payment side of innovative drugs, the national medical insurance catalog will be updated dynamically on a regular basis, and continue to increase the support for innovative drugs with high clinical value The market scale of innovative drugs will be further expanded, and relevant innovative drug enterprises will continue to benefit in the future."